As of 2026-03-19, the Relative Valuation of Tarsus Pharmaceuticals, Inc. (TARS) is (24.27) USD. This relative valuation is based on P/E multiples. With the latest stock price at 69.79 USD, the upside of Tarsus Pharmaceuticals, Inc. based on Relative Valuation is -134.8%.
The range of the Relative Valuation is (16.76) - (25.28) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 10.7x - 18.0x | 16.4x |
| Forward P/E multiples | 9.9x - 16.2x | 14.6x |
| Fair Price | (16.76) - (25.28) | (24.27) |
| Upside | -124.0% - -136.2% | -134.8% |
| Date | P/E |
| 2026-03-17 | -44.72 |
| 2026-03-16 | -44.15 |
| 2026-03-13 | -43.55 |
| 2026-03-12 | -43.68 |
| 2026-03-11 | -44.78 |
| 2026-03-10 | -46.79 |
| 2026-03-09 | -47.73 |
| 2026-03-06 | -46.94 |
| 2026-03-05 | -48.00 |
| 2026-03-04 | -48.83 |
| 2026-03-03 | -49.05 |
| 2026-03-02 | -49.62 |
| 2026-02-27 | -48.39 |
| 2026-02-26 | -48.62 |
| 2026-02-25 | -46.55 |
| 2026-02-24 | -48.07 |
| 2026-02-23 | -44.59 |
| 2026-02-20 | -42.68 |
| 2026-02-19 | -42.00 |
| 2026-02-18 | -40.54 |
| 2026-02-17 | -40.23 |
| 2026-02-13 | -38.95 |
| 2026-02-12 | -40.53 |
| 2026-02-11 | -41.90 |
| 2026-02-10 | -42.23 |
| 2026-02-09 | -41.97 |
| 2026-02-06 | -41.41 |
| 2026-02-05 | -39.72 |
| 2026-02-04 | -40.70 |
| 2026-02-03 | -42.84 |
| 2026-02-02 | -42.25 |
| 2026-01-30 | -41.36 |
| 2026-01-29 | -42.11 |
| 2026-01-28 | -41.13 |
| 2026-01-27 | -43.67 |
| 2026-01-26 | -43.54 |
| 2026-01-23 | -43.80 |
| 2026-01-22 | -45.52 |
| 2026-01-21 | -45.61 |
| 2026-01-20 | -45.45 |
| 2026-01-16 | -45.59 |
| 2026-01-15 | -47.19 |
| 2026-01-14 | -48.21 |
| 2026-01-13 | -48.53 |
| 2026-01-12 | -48.40 |
| 2026-01-09 | -49.26 |
| 2026-01-08 | -50.12 |
| 2026-01-07 | -50.03 |
| 2026-01-06 | -51.19 |
| 2026-01-05 | -51.10 |